



SUPPORT GROUP MONTHLY NEWSLETTER | Connecting CoMMunities!

Happy National Caregiver Month!

IMF Blogs

- October 29: September and October 2026: What's New in Myeloma? [Read here](#)
- October 22: Living With Myeloma: Joyce's Story of Hope, Access, and Advocacy [Read here](#)
- October 15: FAQs on the FDA Accelerated Approval of Zenbexus (Iberdomide) in Combination with Daratumumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma [Read here](#)
- October 8: Day 2: Highlights of the 12th Annual IMF Global Myeloma Action Network Summit [Read here](#)
- September 25: One Mom's Story of Living with Myeloma While Raising Two Children [Read here](#)

Myeloma News and Updates

- The International Myeloma Foundation Launches US Myeloma Network to Accelerate Clinical Trials, Expand Access, and Improve Patient Care [Read here](#)
- Phase 3 MagnetisMM-32 Trial Results: Elrexfio (Elranatamab) Monotherapy Shows Statistically Significant PFS Benefit vs Three Standard Regimens in Relapsed/Refractory Myeloma [Read here](#)
- IMF Plays a Role in the Introduction of the CARE for Blood Cancer Act (H.R. 10858) [Read here](#)
- European Commission Approves Expanded Indication for Teclistamab Monotherapy as Treatment for Relapsed/Refractory Myeloma [Read here](#)
- CHMP Recommends Earlier-Line Use of Talvey (Talquetamab) Plus Daratumumab for Relapsed/Refractory Myeloma [Read here](#)
- Dr. Wee Joo Chng to Receive Asian Myeloma Network Distinguished Service Award at the 10th AMN Summit in Shanghai [Read here](#)
- Phase 3 EXCALIBER-RRMM Trial Results: Zenbexus (Iberdomide) in Combination with Dara and Dex Showed Longer Progression-Free Survival vs Standard of Care in R/R Myeloma [Read here](#)
- Riding with Purpose [Read here](#)
- Myeloma News from the Journals: October [Read here](#)

IMF Videos, Podcasts, Modules & Replays

- Multiple Myeloma Questions Answered: Life With Myeloma, Infections & CAR T [Watch Here](#)
- Could Two Years of Myeloma Maintenance Be Enough? What the ENDURANCE Clinical Trial Found [Watch Here](#)
- Living Well with Myeloma: Embracing Sexuality Through the Cancer Journey - Replay [Watch Here](#)
- A New Multiple Myeloma Drug Is Here: What to Know About Zenbexus [Watch Here](#)
- Myeloma Blood Tests Explained: CBC, M Spike & Light Chains [Watch Here](#)
- Facebook Q&A with Dr. Urvi Shah | September Blood Cancer Awareness Month - Replay [Watch Here](#)
- Why Don't We Treat MGUS? What MGUS Means for Multiple Myeloma Risk [Watch Here](#)



Seminars, Webinars, Workshops and Events

- November 14: In-Person Myeloma Community Workshop 2026 – Phoenix, AZ [Register Now](#)
- November 16: Virtual Myeloma Community Workshop: What's the Right Answer? – Controversies in Myeloma [Register Now](#)

IMF Resources & New/Updated Publications

- Understanding Series October 2026 Updates: VRd Regimen for Newly Diagnosed Myeloma [Read here](#), Immune System in Myeloma [Read here](#)
- Tip Cards Updates: Sarclisa Escena and Sarclisa® [Read here](#)
- Patient Handbook for Multiple Myeloma – Updated September 2026 [Read here](#)
- IMF Resource Library [Learn more](#) | Myeloma Terms and Definitions [Read here](#) | Tip Cards [Read here](#) | Understanding Series – [Read here](#)
- Multiple Myeloma Medications [Read here](#) | Guide to Myeloma Drug Names [Read here](#)
- Clinical Trial Fact Sheets [Read here](#) | ABBV-383 [Read here](#) | K36 [Read here](#)
- Other Resources & Assistance for Caregiving in Myeloma [Read here](#) | Online Resources [Read here](#)

Research Opportunity: Improving Treatment Decision-Making in Relapsed/Refractory Myeloma

IMF's Nurse Leadership Board member, Joseph Tariman, PhD, MBA, RN, ANP-BC, FAAN, is sharing an opportunity to participate in a Creighton University research study evaluating a web-based, AI-enhanced tool designed to help individuals with R/R myeloma better understand treatment options and communicate their preferences. Participation involves using an online decision-support tool and completing brief questionnaires about your experience. Participation is voluntary, and responses will be kept confidential and de-identified.

Important Disclaimer: This study is conducted by Creighton University. IMF did not develop or review the tool being studied and does not endorse the study or the tool. Participation is voluntary and is not connected to IMF programs or services.

Learn more or participate: <https://p3myeloma.net/>

Support Group Meeting Topics & Virtual Speaker Availability Inquire: sgteam@myeloma.org



 [Facebook: /Myeloma](https://www.facebook.com/Myeloma) |  [@IMFMyeloma](https://twitter.com/IMFMyeloma) |  [Instagram @IMFmyeloma](https://www.instagram.com/IMFmyeloma)